NO995620L - Antivirale kombinasjoner inneholdende karbocyklisk nukleosid 1592U89 - Google Patents

Antivirale kombinasjoner inneholdende karbocyklisk nukleosid 1592U89

Info

Publication number
NO995620L
NO995620L NO995620A NO995620A NO995620L NO 995620 L NO995620 L NO 995620L NO 995620 A NO995620 A NO 995620A NO 995620 A NO995620 A NO 995620A NO 995620 L NO995620 L NO 995620L
Authority
NO
Norway
Prior art keywords
combinations containing
carbocyclic nucleoside
containing carbocyclic
antiviral combinations
antiviral
Prior art date
Application number
NO995620A
Other languages
English (en)
Other versions
NO995620D0 (no
Inventor
David Walter Barry
Clair Martha Heider St
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9709945.1A external-priority patent/GB9709945D0/en
Priority claimed from GBGB9719883.2A external-priority patent/GB9719883D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO995620D0 publication Critical patent/NO995620D0/no
Publication of NO995620L publication Critical patent/NO995620L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Det beskrives terapeutiske kombinasjoner av (-)-(1S,4R)-4-[2-amino-6- (cyklopropylamino)-9H-purin-9-yl]-2-cyk!openten-1-metanol (1592U89) og ikke- nukleoside revers transkriptaseinhibitorer som har anti-HIV-virkning: Det beskrives også farmasøytiske blandinger som inneholder de nevnte kombinasjoner og deres anvendelse ved behandlingen av HIV-infeksjoner.
NO995620A 1997-05-17 1999-11-16 Antivirale kombinasjoner inneholdende karbocyklisk nukleosid 1592U89 NO995620L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9709945.1A GB9709945D0 (en) 1997-05-17 1997-05-17 A novel salt
GBGB9719883.2A GB9719883D0 (en) 1997-09-19 1997-09-19 Antiviral combinations
PCT/EP1998/002836 WO1998052570A1 (en) 1997-05-17 1998-05-14 Antiviral combinations containing the carbocyclic nucleoside 1592u89

Publications (2)

Publication Number Publication Date
NO995620D0 NO995620D0 (no) 1999-11-16
NO995620L true NO995620L (no) 2000-01-14

Family

ID=26311543

Family Applications (1)

Application Number Title Priority Date Filing Date
NO995620A NO995620L (no) 1997-05-17 1999-11-16 Antivirale kombinasjoner inneholdende karbocyklisk nukleosid 1592U89

Country Status (12)

Country Link
EP (1) EP0979082A1 (no)
JP (1) JP2001525839A (no)
AR (1) AR012702A1 (no)
AU (1) AU7912398A (no)
BR (1) BR9809127A (no)
CA (1) CA2289655A1 (no)
CO (1) CO4950569A1 (no)
HR (1) HRP980264A2 (no)
MA (1) MA26496A1 (no)
NO (1) NO995620L (no)
PE (1) PE74799A1 (no)
WO (1) WO1998052570A1 (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP990030A2 (en) * 1998-02-17 1999-10-31 Michael B. Maurin Oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors
EP1332757B1 (en) * 1998-05-27 2012-06-13 Merck Sharp & Dohme Corp. Efavirenz compressed tablet formulation
PE20000559A1 (es) * 1998-05-27 2000-07-05 Merck & Co Inc Formulacion de tabletas comprimidas de efavirenz
US20010014352A1 (en) 1998-05-27 2001-08-16 Udit Batra Compressed tablet formulation
WO2013111147A1 (en) * 2011-12-19 2013-08-01 Hetero Research Foundation Extended release compositions of nevirapine
US9457028B2 (en) 2013-02-27 2016-10-04 Kyoto University Pharmaceutical composition for use in prevention or treatment of cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9417249D0 (en) * 1994-08-26 1994-10-19 Wellcome Found A novel salt
MY115461A (en) * 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc

Also Published As

Publication number Publication date
MA26496A1 (fr) 2004-12-20
CO4950569A1 (es) 2000-09-01
WO1998052570A1 (en) 1998-11-26
HRP980264A2 (en) 1999-02-28
BR9809127A (pt) 2000-08-01
AR012702A1 (es) 2000-11-08
EP0979082A1 (en) 2000-02-16
PE74799A1 (es) 1999-08-13
CA2289655A1 (en) 1998-11-26
JP2001525839A (ja) 2001-12-11
NO995620D0 (no) 1999-11-16
AU7912398A (en) 1998-12-11

Similar Documents

Publication Publication Date Title
DE69230140D1 (de) Antivirale nucleosidkombination
FR16C0028I2 (fr) Vecteurs viraux et utilisation de ces derniers dans des methodes therapeutiques
NO20053817L (no) Preparater og fremgangsmater for antiviral kombinasjonsterapi.
MX9204454A (es) Derivados de tiourea para inhibir la replicacion del virus de inmunodeficiencia humana y formulado farmaceutico que los contiene.
EA199700203A1 (ru) Синергические комбинации зидовудина, 1592u89 и 3тс или ftc
BRPI0313664B8 (pt) compostos inibidores de nucleosídeo fosforilase e nucleosidases, suas composições e seus usos
TR199903053T2 (xx) Benzimidazol t�revleri.
DK1469843T3 (da) Komposition til farmaceutisk eller diætetisk anvendelse til at bekæmpe hårtab
BR0307410A (pt) Uso de inibidores de pde5 no tratamento da cicatrização e fibrose
NO995620L (no) Antivirale kombinasjoner inneholdende karbocyklisk nukleosid 1592U89
NO942303L (no)
NO986034L (no) Kombinasjoner omfattende VX 478, ZidovudÞn, FTC og/eller 3TC for anvendelse i behandling av HIV
BG103959A (en) Carbocyclic nucleoside hemisulphate and its application in the treatment of viral infections
BR9916893A (pt) Tratamento
DK0777669T3 (da) 4-[2-amino-6-(cyclopropylamino)-9H-purin-yl]-2-cyclopenten-1-methanolsuccinat som antiviralt middel
DE50212933D1 (de) Die verwendung von pyrimidinnukleosiden und/oder prodrugs davon zur bekämpfung von nebenwirkungen der "haart" (highly active anti-retroviral therapy) und anderen antiviralen therapien
NO995621L (no) Antivirale kombinasjoner inneholdende karbocyklisk nukleoid 1592U89
EA199700150A1 (ru) КОМБИНИРОВАННОЕ ЛЕЧЕНИЕ ПО ПОВОДУ ВИЧ ИНФЕКЦИИ С ИСПОЛЬЗОВАНИЕМ ИНГИБИТОРА ПРОТЕАЗЫ ВИЧ ИНДИНАВИРА И ИНГИБИТОРА ОБРАТНОЙ ТРАНСКРИПТАЗЫ 3TC, НЕОБЯЗАТЕЛЬНО СОВМЕСТНО С AZT, ddI ИЛИ ddC
TR199801439T2 (xx) Herpes simpleks enfeksiyonlar�n�n kombine terapisinde n�kleosit analoglar�.
MXPA04004061A (es) Derivados de quinolina y piridina antiretrovirales.
NO991589L (no) Nye 3-,5- og/eller 6-substituerte analoger av swainsonin, fremgangsmÕter for deres fremstilling og deres anvendelse som terapeutiske midler
DK0722325T3 (da) Præparat til behandling eller forebyggelse af herpes
PT1411956E (pt) Utilizacao de polissacaridos sobre-sulfatados como inibidores de vih
HUP0100365A2 (hu) Kombinációs terápia AIDS kezelésére
ES2189964T3 (es) Combinaciones que comprenden vx478, zidovudina, y 1592u89 para uso en el tratamiento de infecciones por vih.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application